The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmacodynamic (PD) Biomarkers Market Research Report 2025
Synopsis
Global Pharmacodynamic (PD) Biomarkers market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmacodynamic (PD) Biomarkers market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmacodynamic (PD) Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
Merck
Bio-Rad Laboratories
QIAGEN
Roche
Danaher Corporation
Siemens Healthcare
Abbott
Agilent Technologies
Segment by Type
Exposure Biomarkers
Effect Biomarkers
Susceptibility Biomarkers
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmacodynamic (PD) Biomarkers report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Pharmacodynamic (PD) Biomarkers market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmacodynamic (PD) Biomarkers market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmacodynamic (PD) Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
Merck
Bio-Rad Laboratories
QIAGEN
Roche
Danaher Corporation
Siemens Healthcare
Abbott
Agilent Technologies
Segment by Type
Exposure Biomarkers
Effect Biomarkers
Susceptibility Biomarkers
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmacodynamic (PD) Biomarkers report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacodynamic (PD) Biomarkers Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Exposure Biomarkers
1.2.3 Effect Biomarkers
1.2.4 Susceptibility Biomarkers
1.3 Market by Application
1.3.1 Global Pharmacodynamic (PD) Biomarkers Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacodynamic (PD) Biomarkers Market Perspective (2018-2029)
2.2 Pharmacodynamic (PD) Biomarkers Growth Trends by Region
2.2.1 Global Pharmacodynamic (PD) Biomarkers Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmacodynamic (PD) Biomarkers Historic Market Size by Region (2018-2023)
2.2.3 Pharmacodynamic (PD) Biomarkers Forecasted Market Size by Region (2024-2029)
2.3 Pharmacodynamic (PD) Biomarkers Market Dynamics
2.3.1 Pharmacodynamic (PD) Biomarkers Industry Trends
2.3.2 Pharmacodynamic (PD) Biomarkers Market Drivers
2.3.3 Pharmacodynamic (PD) Biomarkers Market Challenges
2.3.4 Pharmacodynamic (PD) Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacodynamic (PD) Biomarkers Players by Revenue
3.1.1 Global Top Pharmacodynamic (PD) Biomarkers Players by Revenue (2018-2023)
3.1.2 Global Pharmacodynamic (PD) Biomarkers Revenue Market Share by Players (2018-2023)
3.2 Global Pharmacodynamic (PD) Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacodynamic (PD) Biomarkers Revenue
3.4 Global Pharmacodynamic (PD) Biomarkers Market Concentration Ratio
3.4.1 Global Pharmacodynamic (PD) Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacodynamic (PD) Biomarkers Revenue in 2022
3.5 Pharmacodynamic (PD) Biomarkers Key Players Head office and Area Served
3.6 Key Players Pharmacodynamic (PD) Biomarkers Product Solution and Service
3.7 Date of Enter into Pharmacodynamic (PD) Biomarkers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacodynamic (PD) Biomarkers Breakdown Data by Type
4.1 Global Pharmacodynamic (PD) Biomarkers Historic Market Size by Type (2018-2023)
4.2 Global Pharmacodynamic (PD) Biomarkers Forecasted Market Size by Type (2024-2029)
5 Pharmacodynamic (PD) Biomarkers Breakdown Data by Application
5.1 Global Pharmacodynamic (PD) Biomarkers Historic Market Size by Application (2018-2023)
5.2 Global Pharmacodynamic (PD) Biomarkers Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharmacodynamic (PD) Biomarkers Market Size (2018-2029)
6.2 North America Pharmacodynamic (PD) Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmacodynamic (PD) Biomarkers Market Size by Country (2018-2023)
6.4 North America Pharmacodynamic (PD) Biomarkers Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacodynamic (PD) Biomarkers Market Size (2018-2029)
7.2 Europe Pharmacodynamic (PD) Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmacodynamic (PD) Biomarkers Market Size by Country (2018-2023)
7.4 Europe Pharmacodynamic (PD) Biomarkers Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacodynamic (PD) Biomarkers Market Size (2018-2029)
8.2 Asia-Pacific Pharmacodynamic (PD) Biomarkers Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmacodynamic (PD) Biomarkers Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmacodynamic (PD) Biomarkers Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmacodynamic (PD) Biomarkers Market Size (2018-2029)
9.2 Latin America Pharmacodynamic (PD) Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmacodynamic (PD) Biomarkers Market Size by Country (2018-2023)
9.4 Latin America Pharmacodynamic (PD) Biomarkers Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacodynamic (PD) Biomarkers Market Size (2018-2029)
10.2 Middle East & Africa Pharmacodynamic (PD) Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmacodynamic (PD) Biomarkers Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmacodynamic (PD) Biomarkers Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Detail
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Pharmacodynamic (PD) Biomarkers Introduction
11.1.4 Thermo Fisher Scientific Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Pharmacodynamic (PD) Biomarkers Introduction
11.2.4 Merck Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.2.5 Merck Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Detail
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Pharmacodynamic (PD) Biomarkers Introduction
11.3.4 Bio-Rad Laboratories Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 QIAGEN
11.4.1 QIAGEN Company Detail
11.4.2 QIAGEN Business Overview
11.4.3 QIAGEN Pharmacodynamic (PD) Biomarkers Introduction
11.4.4 QIAGEN Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.4.5 QIAGEN Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Pharmacodynamic (PD) Biomarkers Introduction
11.5.4 Roche Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Detail
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Pharmacodynamic (PD) Biomarkers Introduction
11.6.4 Danaher Corporation Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.6.5 Danaher Corporation Recent Development
11.7 Siemens Healthcare
11.7.1 Siemens Healthcare Company Detail
11.7.2 Siemens Healthcare Business Overview
11.7.3 Siemens Healthcare Pharmacodynamic (PD) Biomarkers Introduction
11.7.4 Siemens Healthcare Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.7.5 Siemens Healthcare Recent Development
11.8 Abbott
11.8.1 Abbott Company Detail
11.8.2 Abbott Business Overview
11.8.3 Abbott Pharmacodynamic (PD) Biomarkers Introduction
11.8.4 Abbott Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.8.5 Abbott Recent Development
11.9 Agilent Technologies
11.9.1 Agilent Technologies Company Detail
11.9.2 Agilent Technologies Business Overview
11.9.3 Agilent Technologies Pharmacodynamic (PD) Biomarkers Introduction
11.9.4 Agilent Technologies Revenue in Pharmacodynamic (PD) Biomarkers Business (2018-2023)
11.9.5 Agilent Technologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
